The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load

Shinya Hiramitsu, Kenji Miyagishima, Junichi Ishii, Shigeru Matsui, Hiroyuki Naruse, Kenji Shiino, Fumihiko Kitagawa, Yukio Ozaki

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: The clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor, for treatment of postprandial hyperlipidemia was assessed in subjects who ingested a high-fat and high-glucose test meal to mimic westernized diet. Methods: We enrolled 20 male volunteers who had at least one of the following: waist circumference ≥ 85cm, body mass index ≥ 25kg/m2, or triglycerides (TG) from 150 to 400mg/dL. After 4 weeks of treatment with ezetimibe (10mg/day), the subjects ingested a high-fat and high-glucose meal. Then changes in serum lipid and glucose levels were monitored after 0, 2, 4, and 6h, and the area under the curve (AUC) was calculated for the change in each parameter. Results and conclusion: At 4 and 6. h postprandially, TG levels were decreased (p<0.01) after 4 weeks of ezetimibe treatment, and the AUC for TG was also decreased (p<0.01). Apolipoprotein B48 (apo-B48) levels at 4 and 6. h postprandially were significantly decreased after ezetimibe treatment (p<0.01 and p<0.001, respectively), and the AUC for apo-B48 was also significantly decreased (p<0.01). Blood glucose and insulin levels at 2. h postprandially were significantly decreased by ezetimibe (p<0.05). The AUCs for blood glucose and insulin were also significantly decreased (p<0.05 and p<0.01, respectively). Since ezetimibe improved postprandial lipid and glucose metabolism, this drug is likely to be beneficial for dyslipidemia in patients with postprandial metabolic abnormalities.

Original languageEnglish
Pages (from-to)395-400
Number of pages6
JournalJournal of cardiology
Volume60
Issue number5
DOIs
Publication statusPublished - 01-11-2012

Fingerprint

Lipid Metabolism
Fats
Glucose
Area Under Curve
Apolipoprotein B-48
Triglycerides
Meals
Blood Glucose
Anticholesteremic Agents
Insulin
Waist Circumference
Therapeutics
Dyslipidemias
Hyperlipidemias
Ezetimibe
Volunteers
Body Mass Index
Diet
Lipids
Serum

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Hiramitsu, Shinya ; Miyagishima, Kenji ; Ishii, Junichi ; Matsui, Shigeru ; Naruse, Hiroyuki ; Shiino, Kenji ; Kitagawa, Fumihiko ; Ozaki, Yukio. / The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. In: Journal of cardiology. 2012 ; Vol. 60, No. 5. pp. 395-400.
@article{97e6e775ad104251a85caf86a10e399c,
title = "The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load",
abstract = "Objectives: The clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor, for treatment of postprandial hyperlipidemia was assessed in subjects who ingested a high-fat and high-glucose test meal to mimic westernized diet. Methods: We enrolled 20 male volunteers who had at least one of the following: waist circumference ≥ 85cm, body mass index ≥ 25kg/m2, or triglycerides (TG) from 150 to 400mg/dL. After 4 weeks of treatment with ezetimibe (10mg/day), the subjects ingested a high-fat and high-glucose meal. Then changes in serum lipid and glucose levels were monitored after 0, 2, 4, and 6h, and the area under the curve (AUC) was calculated for the change in each parameter. Results and conclusion: At 4 and 6. h postprandially, TG levels were decreased (p<0.01) after 4 weeks of ezetimibe treatment, and the AUC for TG was also decreased (p<0.01). Apolipoprotein B48 (apo-B48) levels at 4 and 6. h postprandially were significantly decreased after ezetimibe treatment (p<0.01 and p<0.001, respectively), and the AUC for apo-B48 was also significantly decreased (p<0.01). Blood glucose and insulin levels at 2. h postprandially were significantly decreased by ezetimibe (p<0.05). The AUCs for blood glucose and insulin were also significantly decreased (p<0.05 and p<0.01, respectively). Since ezetimibe improved postprandial lipid and glucose metabolism, this drug is likely to be beneficial for dyslipidemia in patients with postprandial metabolic abnormalities.",
author = "Shinya Hiramitsu and Kenji Miyagishima and Junichi Ishii and Shigeru Matsui and Hiroyuki Naruse and Kenji Shiino and Fumihiko Kitagawa and Yukio Ozaki",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.jjcc.2012.07.010",
language = "English",
volume = "60",
pages = "395--400",
journal = "Journal of Cardiology",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "5",

}

Hiramitsu, S, Miyagishima, K, Ishii, J, Matsui, S, Naruse, H, Shiino, K, Kitagawa, F & Ozaki, Y 2012, 'The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load', Journal of cardiology, vol. 60, no. 5, pp. 395-400. https://doi.org/10.1016/j.jjcc.2012.07.010

The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. / Hiramitsu, Shinya; Miyagishima, Kenji; Ishii, Junichi; Matsui, Shigeru; Naruse, Hiroyuki; Shiino, Kenji; Kitagawa, Fumihiko; Ozaki, Yukio.

In: Journal of cardiology, Vol. 60, No. 5, 01.11.2012, p. 395-400.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load

AU - Hiramitsu, Shinya

AU - Miyagishima, Kenji

AU - Ishii, Junichi

AU - Matsui, Shigeru

AU - Naruse, Hiroyuki

AU - Shiino, Kenji

AU - Kitagawa, Fumihiko

AU - Ozaki, Yukio

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objectives: The clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor, for treatment of postprandial hyperlipidemia was assessed in subjects who ingested a high-fat and high-glucose test meal to mimic westernized diet. Methods: We enrolled 20 male volunteers who had at least one of the following: waist circumference ≥ 85cm, body mass index ≥ 25kg/m2, or triglycerides (TG) from 150 to 400mg/dL. After 4 weeks of treatment with ezetimibe (10mg/day), the subjects ingested a high-fat and high-glucose meal. Then changes in serum lipid and glucose levels were monitored after 0, 2, 4, and 6h, and the area under the curve (AUC) was calculated for the change in each parameter. Results and conclusion: At 4 and 6. h postprandially, TG levels were decreased (p<0.01) after 4 weeks of ezetimibe treatment, and the AUC for TG was also decreased (p<0.01). Apolipoprotein B48 (apo-B48) levels at 4 and 6. h postprandially were significantly decreased after ezetimibe treatment (p<0.01 and p<0.001, respectively), and the AUC for apo-B48 was also significantly decreased (p<0.01). Blood glucose and insulin levels at 2. h postprandially were significantly decreased by ezetimibe (p<0.05). The AUCs for blood glucose and insulin were also significantly decreased (p<0.05 and p<0.01, respectively). Since ezetimibe improved postprandial lipid and glucose metabolism, this drug is likely to be beneficial for dyslipidemia in patients with postprandial metabolic abnormalities.

AB - Objectives: The clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor, for treatment of postprandial hyperlipidemia was assessed in subjects who ingested a high-fat and high-glucose test meal to mimic westernized diet. Methods: We enrolled 20 male volunteers who had at least one of the following: waist circumference ≥ 85cm, body mass index ≥ 25kg/m2, or triglycerides (TG) from 150 to 400mg/dL. After 4 weeks of treatment with ezetimibe (10mg/day), the subjects ingested a high-fat and high-glucose meal. Then changes in serum lipid and glucose levels were monitored after 0, 2, 4, and 6h, and the area under the curve (AUC) was calculated for the change in each parameter. Results and conclusion: At 4 and 6. h postprandially, TG levels were decreased (p<0.01) after 4 weeks of ezetimibe treatment, and the AUC for TG was also decreased (p<0.01). Apolipoprotein B48 (apo-B48) levels at 4 and 6. h postprandially were significantly decreased after ezetimibe treatment (p<0.01 and p<0.001, respectively), and the AUC for apo-B48 was also significantly decreased (p<0.01). Blood glucose and insulin levels at 2. h postprandially were significantly decreased by ezetimibe (p<0.05). The AUCs for blood glucose and insulin were also significantly decreased (p<0.05 and p<0.01, respectively). Since ezetimibe improved postprandial lipid and glucose metabolism, this drug is likely to be beneficial for dyslipidemia in patients with postprandial metabolic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=84868619241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868619241&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2012.07.010

DO - 10.1016/j.jjcc.2012.07.010

M3 - Article

C2 - 22890076

AN - SCOPUS:84868619241

VL - 60

SP - 395

EP - 400

JO - Journal of Cardiology

JF - Journal of Cardiology

SN - 0914-5087

IS - 5

ER -